{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T20:23:55Z","timestamp":1792873435918,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T00:00:00Z","timestamp":1696636800000},"content-version":"vor","delay-in-days":371,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.jacc.2022.07.027","type":"journal-article","created":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T17:40:27Z","timestamp":1664214027000},"page":"1287-1298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":152,"title":["Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes"],"prefix":"10.1016","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0902-6798","authenticated-orcid":false,"given":"Paul","family":"Lacaze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Bakshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moeen","family":"Riaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina","family":"Polekhina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harpreet S.","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8402-7435","authenticated-orcid":false,"given":"Pradeep","family":"Natarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory","family":"Wolfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Beilin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Nicholls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald F.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"McNeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Tonkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9834-9494","authenticated-orcid":false,"given":"Sotirios","family":"Tsimikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2022.07.027_bib1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/MED.0000000000000237","article-title":"Lp (a) as a new target for reduction of risk of cardiovascular disease and emergence of novel therapies to lower Lp (a)","volume":"23","author":"Tsimikas","year":"2016","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.jacc.2022.07.027_bib2","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2022.07.027_bib3","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2022.07.027_bib4","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2022.07.027_bib5","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1161\/ATVBAHA.116.308011","article-title":"Prevalence of elevated Lp(a) mass levels and patient thresholds in 532 359 patients in the United States","volume":"36","author":"Varvel","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2022.07.027_bib6","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2022.07.027_bib7","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jacc.2017.11.014","article-title":"NHLBI Working Group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis","volume":"71","author":"Tsimikas","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2022.07.027_bib8","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1093\/eurheartj\/ehaa649","article-title":"Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial","volume":"41","author":"Szarek","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2022.07.027_bib9","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1161\/01.CIR.96.8.2751","article-title":"Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association","volume":"96","author":"Hennekens","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2022.07.027_bib10","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1194\/jlr.R060582","article-title":"Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?","volume":"57","author":"Boffa","year":"2016","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2022.07.027_bib11","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1161\/01.ATV.18.9.1393","article-title":"Apolipoprotein(a) enhances platelet responses to the thrombin receptor-activating peptide SFLLRN","volume":"18","author":"Rand","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2022.07.027_bib12","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1055\/s-0037-1615654","article-title":"Binding of recombinant apolipoprotein(a) to human platelets and effect on platelet aggregation","volume":"85","author":"Martinez","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2022.07.027_bib13","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/nm1626","article-title":"Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype","volume":"13","author":"Podrez","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2022.07.027_bib14","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/cvr\/cvab017","article-title":"Relationship between lipoproteins, thrombosis, and atrial fibrillation","volume":"118","author":"Ding","year":"2022","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacc.2022.07.027_bib15","first-page":"1","article-title":"Clinical utility of lipoprotein(a) and LPA genetic risk score in risk prediction of incident atherosclerotic cardiovascular disease","volume":"6","author":"Trinder","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2022.07.027_bib16","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2022.07.027_bib17","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.atherosclerosis.2008.07.019","article-title":"Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy","volume":"203","author":"Chasman","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2022.07.027_bib18","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1161\/ATVBAHA.107.141291","article-title":"A\u00a0polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease","volume":"27","author":"Luke","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2022.07.027_bib19","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1161\/ATVBAHA.107.153981","article-title":"Association of gene variants with incident myocardial infarction in the Cardiovascular Health Study","volume":"28","author":"Shiffman","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2022.07.027_bib20","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1805819","article-title":"Effect of aspirin on cardiovascular events and bleeding in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2022.07.027_bib21","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1056\/NEJMoa1800722","article-title":"Effect of aspirin on disability-free survival in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2022.07.027_bib22","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.cct.2013.09.014","article-title":"Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial","volume":"36","year":"2013","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.jacc.2022.07.027_bib23","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nature15393","article-title":"A\u00a0global reference for\u00a0human genetic variation","volume":"526","author":"Auton","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jacc.2022.07.027_bib24","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/ng.3656","article-title":"Next-generation genotype imputation service and methods","volume":"48","author":"Das","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.jacc.2022.07.027_bib25","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1006\/bbrc.1996.1547","article-title":"An in\u00a0vitro system for identifying agents capable of changing serum lipoprotein(a) concentration by regulating the transcriptional activity of the apolipoprotein(a) gene promoter","volume":"227","author":"Azuma","year":"1996","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jacc.2022.07.027_bib26","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1093\/clinchem\/48.9.1454","article-title":"Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases","volume":"48","author":"Akaike","year":"2002","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacc.2022.07.027_bib27","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.atherosclerosis.2009.09.077","article-title":"The I4399M variant of apolipoprotein(a) is associated with increased oxidized phospholipids on apolipoprotein B-100 particles","volume":"209","author":"Arai","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2022.07.027_bib28","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1373\/clinchem.2017.276931","article-title":"High lipoprotein(a) and Low Risk of major bleeding in brain and airways in the general population: a Mendelian randomization study","volume":"63","author":"Langsted","year":"2017","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacc.2022.07.027_bib29","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1111\/jth.13759","article-title":"Characterization of the I4399M variant of apolipoprotein(a): implications for altered prothrombotic properties of lipoprotein(a)","volume":"15","author":"Scipione","year":"2017","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jacc.2022.07.027_bib30","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1161\/CIRCULATIONAHA.116.024611","article-title":"LPA gene, ethnicity, and cardiovascular events","volume":"135","author":"Lee","year":"2017","journal-title":"Circulation"}],"updated-by":[{"DOI":"10.1016\/j.jacc.2022.10.002","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T00:00:00Z","timestamp":1668470400000}}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109722057205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109722057205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T23:54:11Z","timestamp":1696636451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109722057205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":30,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0735109722057205"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2022.07.027","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742348404.793595838","asserted-by":"object"}]},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2022.07.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}